Literature DB >> 24683496

Analysis of the Distribution and Temporal Trends of Grade and Stage in Urothelial Bladder Cancer in Northern New England from 1994 to 2004.

Alan R Schned1, Petra Lenz2, Lee E Moore3, Alison Johnson4, Michael Jones5, Masatoshi Kida6, Debra T Silverman3, Molly Schwenn7, Karl T Kelsey8, Angeline S Andrew9, Dalsu Baris3, Margaret R Karagas9.   

Abstract

We investigate the distribution of bladder tumor category and stage in Northern New England by geographic region, smoking status and over time. 1091 incident bladder cancer cases from the New England Bladder Cancer Study (NEBCS), a large population-based case-control study carried out in Maine, New Hampshire and Vermont (2001-2004), and 680 bladder cancer cases from previous case-control studies in New Hampshire (1994-2000) were used in the analysis. Of 1091 incident bladder cancer cases from the NEBCS, 26.7% of tumors were papillary urothelial neoplasms of low malignant potential (PUNLMP), 26.8% low-grade papillary urothelial carcinomas (PUC-LG), 31.3% high-grade papillary urothelial carcinomas (PUC-HG), 9.1% non-papillary urothelial carcinomas (non-PUC), and 4.3% carcinoma in situ (CIS). Approximately 70% of cases were non-invasive (Tis/Ta), and all PUNLMP cases were of the Ta category. By contrast, half of all PUC-HG carcinomas were invasive. Short-term time trend analysis within the NEBCS (2001-2004) indicated an increase in the percentage of PUNLMP (p-trend<0.0001) paralleled by a decrease in PUC-LG (p-trend=0.02), and for PUC-LG an increase in the percentage of non-invasive tumors (p-trend 0.04). Our findings suggest possible short-term trends with an increase in the percentage of PUNLMP and a change in the percentage of PUC-LG towards non-invasive disease.

Entities:  

Year:  2012        PMID: 24683496      PMCID: PMC3966206          DOI: 10.5402/2012/283670

Source DB:  PubMed          Journal:  ISRN Pathol        ISSN: 2090-5718


  22 in total

1.  Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

Authors:  Hervé Wallerand; Ashraf A Bakkar; Sixtina Gil Diez de Medina; Jean-Claude Pairon; Yu-Ching Yang; Dimitri Vordos; Hugues Bittard; Sylvie Fauconnet; Jean-Claude Kouyoumdjian; Marie-Claude Jaurand; Zuo-Feng Zhang; François Radvanyi; Jean-Paul Thiery; Dominique K Chopin
Journal:  Carcinogenesis       Date:  2004-09-03       Impact factor: 4.944

Review 2.  Morphological diagnosis of urothelial neoplasms.

Authors:  R Montironi; R Mazzucchelli; M Scarpelli; A Lopez-Beltran; L Cheng
Journal:  J Clin Pathol       Date:  2007-06-01       Impact factor: 3.411

3.  A case-control study of smoking and bladder cancer risk: emergent patterns over time.

Authors:  Dalsu Baris; Margaret R Karagas; Castine Verrill; Alison Johnson; Angeline S Andrew; Carmen J Marsit; Molly Schwenn; Joanne S Colt; Sai Cherala; Claudine Samanic; Richard Waddell; Kenneth P Cantor; Alan Schned; Nathaniel Rothman; Jay Lubin; Joseph F Fraumeni; Robert N Hoover; Karl T Kelsey; Debra T Silverman
Journal:  J Natl Cancer Inst       Date:  2009-11-16       Impact factor: 13.506

Review 4.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

5.  Prospective registration of all patients in a geographical region with newly diagnosed bladder carcinomas during a two-year period.

Authors:  S Holmäng; H Hedelin; C Anderström; E Holmberg; S L Johansson
Journal:  Scand J Urol Nephrol       Date:  2000-04

Review 6.  Epidemiology of bladder cancer.

Authors:  D T Silverman; P Hartge; A S Morrison; S S Devesa
Journal:  Hematol Oncol Clin North Am       Date:  1992-02       Impact factor: 3.722

7.  Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.

Authors:  Kevin A David; Katherine Mallin; Matthew I Milowsky; Jamie Ritchey; Peter R Carroll; David M Nanus
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

Review 8.  Staging and reporting of urothelial carcinoma of the urinary bladder.

Authors:  Liang Cheng; Rodolfo Montironi; Darrell D Davidson; Antonio Lopez-Beltran
Journal:  Mod Pathol       Date:  2009-06       Impact factor: 7.842

9.  Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire.

Authors:  Margaret R Karagas; Tor D Tosteson; J Steven Morris; Eugene Demidenko; Leila A Mott; John Heaney; Alan Schned
Journal:  Cancer Causes Control       Date:  2004-06       Impact factor: 2.506

10.  Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States.

Authors:  Alan R Schned; Angeline S Andrew; Carmen J Marsit; Karl T Kelsey; Michael S Zens; Margaret R Karagas
Journal:  Scand J Urol Nephrol       Date:  2008
View more
  2 in total

Review 1.  Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.

Authors:  Philipp Maisch; Alex Koziarz; Jon Vajgrt; Vikram Narayan; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2021-12-01

2.  Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic.

Authors:  Dalsu Baris; Richard Waddell; Laura E Beane Freeman; Molly Schwenn; Joanne S Colt; Joseph D Ayotte; Mary H Ward; John Nuckols; Alan Schned; Brian Jackson; Castine Clerkin; Nathaniel Rothman; Lee E Moore; Anne Taylor; Gilpin Robinson; Gm Monawar Hosain; Karla R Armenti; Richard McCoy; Claudine Samanic; Robert N Hoover; Joseph F Fraumeni; Alison Johnson; Margaret R Karagas; Debra T Silverman
Journal:  J Natl Cancer Inst       Date:  2016-05-02       Impact factor: 13.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.